PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10

作者：

Xiao, Jun ^{[1
]}

Deng, Yi-Min ^{[1
]}

Liu, Xiang-Rui ^{[1
]}

Cao, Jian-Ping ^{[2
]}

Zhou, Min ^{[1
]}

Tang, Ya-Ling ^{[1
]}

Xiong, Wen-Hao ^{[1
]}

Jiang, Zhi-Sheng ^{[1
]}

Tang, Zhi-Han ^{[1
]}

Liu, Lu-Shan ^{[1
]}

机构：

[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China

[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China

来源：

CLINICA CHIMICA ACTA | 2019年 / 495卷

基金：

中国国家自然科学基金;

关键词：

Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;

D O I：

10.1016/j.cca.2019.05.005

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.

引用

页码：358 / 364

页数：7

共 50 条

[1] PCSK9 and Atherosclerosis - Lipids and Beyond
Shapiro, Michael D.
Fazio, Sergio
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (05) : 462 - 472
[2] PCSK9: A key factor modulating atherosclerosis
Li, Sha
Li, Jian-Jun
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (03) : 221 - 230
[3] An Update on the Role of PCSK9 in Atherosclerosis
Yurtseven, Ece
Ural, Dilek
Baysal, Kemal
Tokgozoglu, Lale
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2020, 27 (09) : 909 - 918
[4] Role Of Retinoid X Receptor In Regulating Pcsk9 Transcription In The Liver And Atherosclerosis
Choubey, Mayank
Wang, Xiang
Tirumalasetty, Munichandra
Yadav, Pradeep K.
Ansari, Abulaish
Rajan, Sujith
Hu, Wenquan
Hussain, M. M.
Miao, Qing R.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
[5] Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice
Yan, Li
Jia, Qingling
Cao, Hui
Chen, Chuan
Xing, Sanli
Huang, Yan
Shen, Dingzhu
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
[6] Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Seidah, Nabil G.
Garcon, Damien
CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (10) : 821 - 830
[7] PCSK9: A novel inflammation modulator in atherosclerosis?
Tang, Zhi-Han
Li, Tao-Hua
Peng, Juan
Zheng, Jie
Li, Ting-Ting
Liu, Lu-Shan
Jiang, Zhi-Sheng
Zheng, Xi-Long
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2345 - 2355
[8] Mechanisms of Direct PCSK9 Effect on Atherosclerosis
Giunzioni, Ilaria
Tavori, Hagai
Predazzi, Irene M.
Ding, Lei
Zhang, Youmin
Linton, MacRae F.
Fazio, Sergio
CIRCULATION RESEARCH, 2014, 115 (12) : E91 - E91
[9] Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis
Cui, Jun
Qiu, Yuxiang
Kang, Ningsu
Lu, Jianxun
Zheng, Lu
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12) : 1430 - 1437
[10] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi-Borojeni, Amir Abbas
Banach, Maciej
Ruscica, Massimiliano
Sahebkar, Amirhossein
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208

← 1 2 3 4 5 →